The Evolving Concept of Management and Treatment of Liver Diseases

HELM
Humanitas Educational Liver Meeting

Rozzano - December 13/14, 2015

Con il patrocinio di:

In collaborazione con:

Scientific Coordinator

Savino Bruno
Full Professor of Medicine
Humanitas University Medicine (HUNIMED)
Director of the Department of Internal Medicine
IRCCS Istituto Clinico Humanitas – Rozzano, Milano

Faculty

Alessio **Aghemo** *(Milan, Italy)*
Alfredo **Alberti** *(Padova, Italy)*
Tarik **Asselah** *(Paris, France)*
Marc **Bourliere** *(Marseille, France)*
Savino **Bruno** *(Milan, Italy)*
Raffaele **Bruno** *(Pavia, Italy)*
Marco **Carbone** *(Milan, Italy)*
Massimo **Colombo** *(Milan, Italy)*
Antonio **Craxì** *(Palermo, Italy)*
Roberto **De Franchis** *(Milan, Italy)*
Rafael **Esteban Mur** *(Barcelona, Spain)*
Pietro **Invernizzi** *(Milan, Italy)*
Pietro **Lampertico** *(Milan, Italy)*
Alberto **Malesci** *(Milan, Italy)*
Alberto **Mantovani** *(Milan, Italy)*
Mario **Mondelli** *(Pavia, Italy)*
Marco **Montorsi** *(Milan, Italy)*
Lorenza **Rimassa** *(Milan, Italy)*
Massimo **Roncalli** *(Milan, Italy)*
Armando **Santoro** *(Milan, Italy)*
Guido **Torzilli** *(Milan, Italy)*
Stefan **Zeuzem** *(Frankfurt, Germany)*

Scientific Rationale

The Hepatitis C virus represents, and is expected to represent in the near future, one of the major causes of chronic liver disease in our country, also due to the current immigration flows. In this rapidly changing field, more and more drugs offer interesting treatment perspectives. However, on the basis of costs Pros and cons of universal vs restricted treatment should be discussed.

Moreover, in order to improve the choice of treatment schedules, on- and off-label combination results of new molecules in different clinical setting requires a proper discussion.

Not least, the role of currently available second wave PIs in combination with PEG and RBV in patients without cirrhosis, remains to be accessed. In addition, the residual task of IFN-based therapy in some subset of genotype 3 patients, on the basis of poor efficacy of IFN –Free combination should be assessed, as well while the impact of HCC and decompensated disease in this scenario deserve a careful debate.

The Meeting is targeted to specialists in Internal Medicine, Hepatology, Gastroenterology, and Infectious Diseases, aiming to provide them with the opportunity to interact with the Experts and discuss all the clinical issues of Chronic Hepatitis C and its complication. Several other important topics aimed at improve the quality of management of patients with liver diseases will also be afforded.

Scientific Program | December 13, 2015

17.30 - 18.00 **Registration**

18.00 - 18.30 **Course presentation**
S. Bruno, M. Montorsi

18.30 - 19.00 STATE OF THE ART LECTURE
Treatment of Hepatitis C: how short is possible – how long is necessary?
S. Zeuzem

Scientific Program | December 14, 2015

OPENING LECTURE
Presenter: **M. Mondelli**

09.15 - 09.45 **State of the art lecture**
A. Mantovani

SESSION 1
Hepatocellular Carcinoma
Chairman: **A. Santoro**

09.45 - 10.05 **Biomolecular markers in HCC**
M. Roncalli

10.05 - 10.25 **Systemic therapy of advanced HCC**
L. Rimassa

10.25 - 10.45 **Surgery: an evolving of involving role for these patients?**
G. Torzilli

10.45 - 11.00 **Discussion**

11.00 - 11.20 COFFEE BREAK

SESSION 2
HCV Hepatitis in the Era of Direct Antiviral Agents (DAAs)
Chairmen: **A. Alberti, S. Bruno**

11.20 - 11.40 LECTURE
Treatment of cirrhotic patients in the era of DAAs. Will SVR still remain an useful surrogate marker of disease outcome?
M. Colombo

11.40 - 12.00 LECTURE
How can we fill the time-gap until the universal treatment? Pharmacoeconomics and ethical considerations
A. Craxì

12.00 - 12.20 LECTURE
On- and off-label all-oral DAAs. Light and shadow
M. Bourliere

12.20 - 12.40 LECTURE
What's the better DAAs combination for patients who failed triple therapy with first generation PIs?
T. Asselah

Scientific Program | December 14, 2015

12.40 - 13.00 LECTURE
The future for liver transplant without HCV
R. Esteban Mur

13.00 - 14.15 LUNCH

14.15 - 15.35 **Special populations: are they changed with the new DAAs? The role of comorbidities and DDI's while using DDAs**
R. Bruno

15.35 - 15.55 **A review of International guidelines**
A. Aghemo

SESSION 3
NON HCV HEPATITIS
Chairman: **A. Malesci**

15.55 - 16.15 **Novel Treatments in primary biliary cirrhosis**
P. Invernizzi

16.15 - 16.35 **Risk Stratification in Autoimmune Liver Diseases**
M. Carbone

16.35 - 16.55 **BAVENO 6TH**
Report of Consensus Conference
R. De Franchis

16.55 - 17.15 **Update on Hepatitis B Therapy**
P. Lampertico

17.15 - 17.30 **Concluding Remarks**

Informazioni Generali

SEDE CONGRESSUALE

Centro Congressi
Istituto Clinico Humanitas
Via Alessandro Manzoni, 56 - 20089 Rozzano MI

ISCRIZIONE

L'iscrizione è gratuita e comprende:

- *Iscrizione al Convegno*
- *Badge di accesso alle Sessioni Scientifiche*
- *Pausa caffè*
- *Colazione di lavoro*
- *Attestato di partecipazione*

L'accesso ai lavori scientifici sarà consentito esclusivamente agli iscritti al Convegno in possesso del badge.

LINGUA UFFICIALE

ITALIANO.
Non è prevista traduzione simultanea (inglese/italiano) nelle sessioni tenute da relatori stranieri.

ATTESTATI DI PARTECIPAZIONE

L'attestato di partecipazione sarà consegnato a tutti i partecipanti regolarmente iscritti che ne faranno richiesta presso il desk della Segreteria al termine dei lavori congressuali.

CREDITI ECM

Questo Convegno darà diritto a
n. **5,3 crediti ECM** per l'anno 2015.

Il convegno è accreditato per le figure professionali di **Biologo e Medico Chirurgo** (Discipline: Chirurgia Generale, Gastroenterologia, Malattie Infettive, Medicina Interna, Microbiologia e Virologia, Oncologia).

Per la certificazione ECM è assolutamente indispensabile compilare in ogni sua parte (in particolare nome e cognome, data e luogo di nascita, codice fiscale, numero dio iscrizione all'albo professionale e indirizzo e-mail) il Modulo Dati ECM, la scheda di valutazione ed il questionario di apprendimento. Durante il Convegno dovrete registrare la vostra presenza in aula ad inizio e fine lavori.

ATTENZIONE: per conseguire i crediti formativi sarà necessario garantire la propria presenza al 100% del tempo totale, rispondere correttamente al 75% delle domande contenute nel questionario di valutazione dell'apprendimento, compilare tutta la modulistica e riconsegnarla al termine del Convegno alla postazione ECM presso la Segreteria.

CON IL CONTRIBUTO NON CONDIZIONATO DI

abbvie

Bayer HealthCare
Bayer Schering Pharma

Bristol-Myers Squibb

GILEAD

janssen
PHARMACEUTICAL COMPANIES OF Johnson&Johnson

MSD

Segreteria Organizzativa

START promotion

Start Promotion S.r.l.
Via Mauro Macchi, 50 - 20124 Milano
T: 02 67071383 | F: 02 67072294
info@startpromotion.it | www.startpromotion.it